At Sankalp India Foundation, every step we take is guided by one simple principle—to give children and young people living with thalassemia the safest and best possible care. Blood transfusions form the backbone of thalassemia management, and ensuring their safety is non-negotiable. That is why we are proud to share a significant step forward: bringing Glucose-6-Phosphate Dehydrogenase (G6PD) testing in-house at Sankalp Labs.
Why G6PD Testing Matters
G6PD deficiency is one of the most common enzyme deficiencies worldwide. For individuals with thalassemia who depend on lifelong transfusions, knowing whether the donor blood is safe is critical. A deficiency in G6PD can put patients at risk of complications, making this test an essential part of transfusion safety.
Until now, G6PD testing was outsourced, which often meant higher costs and delays in receiving results. For families who already face the emotional and financial strain of thalassemia care, these delays could add unnecessary stress.
What Changes with In-House Testing
By moving G6PD testing into our own laboratories, we are transforming both speed and cost-efficiency of care:
- Faster Results: No more waiting for outsourced labs. Reports will now be available much sooner, allowing timely transfusions without compromise.
- Reduced Costs: In-house testing brings down expenses significantly, making safe care more accessible to families.
- Greater Efficiency: With better control over the process, we can ensure higher consistency and reliability in testing.
A Commitment to Safer Care
This development is more than just a laboratory upgrade—it is a promise. A promise to every patient and family that we will continue to innovate and strengthen systems so that their care is safe, reliable, and compassionate.
At our thalassemia day care centres, we see the difference every small improvement makes. For parents, it is the reassurance that their child is receiving the safest possible blood. For patients, it is the confidence that their treatment is in trusted hands. And for us, it is the satisfaction of staying true to our mission: a thalassemia-free India, built on care that is safe, affordable, and accessible.
What’s Next?
The introduction of G6PD testing in-house is just the beginning. As this initiative unfolds, we will continue to share updates, insights, and outcomes—because every step forward is a step we take together with the community that supports us.